Your browser doesn't support javascript.
loading
Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data.
Huynh, Christine; Seeland, Swen; Segrestaa, Jerome; Gnerre, Carmela; Hogeback, Jens; Meyer Zu Schwabedissen, Henriette E; Dingemanse, Jasper; Sidharta, Patricia N.
Afiliación
  • Huynh C; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Seeland S; Department of Pharmaceutical Sciences, Biopharmacy, University of Basel, Basel, Switzerland.
  • Segrestaa J; Department of Preclinical Drug Metabolism and Pharmacokinetics, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Gnerre C; Department of Preclinical Drug Metabolism and Pharmacokinetics, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Hogeback J; Department of Preclinical Drug Metabolism and Pharmacokinetics, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Meyer Zu Schwabedissen HE; A&M Labor für Analytik und Metabolismusforschung Service GmbH, Bergheim, Germany.
  • Dingemanse J; Department of Pharmaceutical Sciences, Biopharmacy, University of Basel, Basel, Switzerland.
  • Sidharta PN; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
Front Pharmacol ; 13: 812065, 2022.
Article en En | MEDLINE | ID: mdl-35431953
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Suiza
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Suiza